Sameer Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sameer Gupta has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- David Michael Miller
Department of Medicine, Division Of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
8 shared publications - Isaac Brownell
Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
7 shared publications - Howard L. Kaufman
Center for Cutaneous Oncology, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, USA
6 shared publications - Kevin Scott Emerick
Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA
5 shared publications - Vishal Anil Patel
Department of Dermatology, George Washington University, Washington, DC
4 shared publications Massachusetts General Hospital
3 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 3 (2)
Evolving Standards for Resected High-Risk CSCC: Integrating Insights from C-POST and KEYNOTE-630
This perspective summarizes a multidisciplinary discussion of the C-POST trial, which demonstrated improved disease-free survival with adjuvant cemiplimab in patients with resected high-risk cutaneous squamous cell carcinoma (CSCC). Participants reflected on evolving practice patterns and considered the contrasting futility outcome of adjuvant pembrolizumab in the KEYNOTE-630 study. To help explore potential reasons for these divergent results, this piece incorporates reconstructed survival data—estimates derived from published Kaplan-Meier curves in the absence of individual patient data. The discussion underscores both the enthusiasm and the remaining uncertainty surrounding adjuvant immunotherapy in CSCC.
- 1 January 2025
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 3 (2)
Open AccessEvolving Standards for Resected High-Risk CSCC: Integrating Insights from C-POST and KEYNOTE-630
This perspective summarizes a multidisciplinary discussion of the C-POST trial, which demonstrated improved disease-free survival with adjuvant cemiplimab in patients with resected high-risk cutaneous squamous cell carcinoma (CSCC). Participants reflected on evolving practice patterns and considered the contrasting futility outcome of adjuvant pembrolizumab in the KEYNOTE-630 study. To help explore potential reasons for these divergent results, this piece incorporates reconstructed survival data—estimates derived from published Kaplan-Meier curves in the absence of individual patient data. The discussion underscores both the enthusiasm and the remaining uncertainty surrounding adjuvant immunotherapy in CSCC.
- Open Access
- 1 January 2025
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 3 (1)
The Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities
This perspective discusses the evolving role of circulating tumor DNA (ctDNA) in the management of Merkel Cell Carcinoma, highlighting findings from a recent multicenter study and insights from a multi-institutional Journal Club. Key opportunities and challenges related to ctDNA’s use in surveillance and treatment decision-making are explored.
- 1 January 2025
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 3 (1)
Open AccessThe Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities
This perspective discusses the evolving role of circulating tumor DNA (ctDNA) in the management of Merkel Cell Carcinoma, highlighting findings from a recent multicenter study and insights from a multi-institutional Journal Club. Key opportunities and challenges related to ctDNA’s use in surveillance and treatment decision-making are explored.
- Open Access
- 24 January 2024
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 2 (1)
A Closer Look: Evaluating Mohs Surgery's Role in the Treatment of Invasive Melanoma of the Head and Neck
In this Perspectives on the Science piece, we reflect on the implications of the recently conducted multicenter study on the treatment of invasive head and neck melanoma using Mohs micrographic surgery.
- 24 January 2024
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 2 (1)
Open AccessA Closer Look: Evaluating Mohs Surgery's Role in the Treatment of Invasive Melanoma of the Head and Neck
In this Perspectives on the Science piece, we reflect on the implications of the recently conducted multicenter study on the treatment of invasive head and neck melanoma using Mohs micrographic surgery.
- Open Access
- 30 July 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (2)
To Screen or Not To Screen, That is the Question
In this Perspectives on the Science piece we reflect on the impact of the recent USPSTF recommendation statement on skin cancer screening.
- 30 July 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (2)
Open AccessTo Screen or Not To Screen, That is the Question
In this Perspectives on the Science piece we reflect on the impact of the recent USPSTF recommendation statement on skin cancer screening.
- Open Access
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (2)
Adjuvant anti-PD-1 for Merkel Cell Carcinoma: Ready for the Clinic?
In this Perspectives on the Science piece we reflect on the recently published ADMEC-O trial.
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (2)
Open AccessAdjuvant anti-PD-1 for Merkel Cell Carcinoma: Ready for the Clinic?
In this Perspectives on the Science piece we reflect on the recently published ADMEC-O trial.
- Open Access
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (1)
Immunotherapy and Cardiovascular Health - A Cause for Concern?
In this Perspectives on the Science piece we reflect on the impact of ‘Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque’ by Drobni et al.
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (1)
Open AccessImmunotherapy and Cardiovascular Health - A Cause for Concern?
In this Perspectives on the Science piece we reflect on the impact of ‘Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque’ by Drobni et al.
- Open Access
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (1)
Skin Cancer Chemoprevention for Solid Organ Transplant Recipients - The Search Continues
In this Perspectives on the Science piece, we reflect on the impact of the recently published ONTRANS trial.
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (1)
Open AccessSkin Cancer Chemoprevention for Solid Organ Transplant Recipients - The Search Continues
In this Perspectives on the Science piece, we reflect on the impact of the recently published ONTRANS trial.
- Open Access
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (1)
Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?
In this Perspectives on the Science piece we reflect on the impact of the recently published SWOG S1801 trial.
- 1 January 2023
- Published by Society of Cutaneous Oncology in Journal of Cutaneous Oncology
- Vol. 1 (1)
Open AccessPerioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?
In this Perspectives on the Science piece we reflect on the impact of the recently published SWOG S1801 trial.
- Open Access
- 2 September 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (6) , 100152
New Insights into Melanoma Tumor Syndromes
- 2 September 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (6) , 100152
Open AccessNew Insights into Melanoma Tumor Syndromes
- 28 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 170-172
The Association of Neighborhood-Level Socioeconomic Status and Tumor Diameter in Squamous Cell Carcinoma
- 28 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 170-172
The Association of Neighborhood-Level Socioeconomic Status and Tumor Diameter in Squamous Cell Carcinoma